(1) 转运体结构生物学
(2) 靶向转运体药物开发

研究主要聚焦与重大疾病密切相关的转运体，包括：1）系统揭示多种神经递质转运体（包括去甲肾上腺素、多巴胺、甘氨酸转运体）的工作机制及药物调控方式，为抑郁、注意缺陷多动障碍、精神分裂症等精神疾病新型药物的研发提供了结构基础。相关成果共同入选2024年度“中国科学十大进展”。2）阐释了尿酸转运蛋白URAT1的工作及调控机制。

(1) Yu Z#, Hu T#, Su J#, Zhao J#, Li R, Ma Q, Chen Q, Bai Q, Dong Y, Yuan P, Li N*, Zhang XC*, Zhao Y*. Molecular mechanism of drug inhibition of URAT1. Nat Commun. 2025 Jul 16;16(1):6551. doi: 10.1038/s41467-025-61226-x. PMID: 40670375; PMCID: PMC12267519. (IF:15.7)
(2) Hu T#, Yu Z#, Zhao J#, Meng Y, Salomon K, Bai Q, Wei Y, Zhang J, Xu S, Dai Q, Yu R, Yang B, Loland CJ*, Zhao Y*. Transport and inhibition mechanisms of the human noradrenaline transporter. Nature. 2024 Aug;632(8026):930-937. doi: 10.1038/s41586-024-07638-z. Epub 2024 Jul 31. PMID: 39085602. (IF:50.5)
(3) Li Y#, Wang X#, Meng Y#, Hu T#, Zhao J#, Li R, Bai Q, Yuan P, Han J, Hao K, Wei Y, Qiu Y, Li N, Zhao Y*. Dopamine reuptake and inhibitory mechanisms in human dopamine transporter. Nature. 2024 Aug;632(8025):686-694. doi: 10.1038/s41586-024-07796-0. Epub 2024 Aug 7. PMID: 39112701. (IF:50.5).
(4) Wei Y#, Li R#, Meng Y#, Hu T#, Zhao J#, Gao Y, Bai Q, Li N, Zhao Y*. Transport mechanism and pharmacology of the human GlyT1. Cell. 2024 Mar 28;187(7):1719-1732.e14. doi: 10.1016/j.cell.2024.02.026. Epub 2024 Mar 20. PMID: 38513663. (IF:42.5)
(5) Zhang P, Wang K, Hu T, Xu M, You X, Chen M, Tang X, Hu H, Jiang Y, Zhao W, Tan S*. A novel fully human anti-NT-ANGPTL3 antibody from phage display library exhibits potent ApoB, TG, and LDL-C lowering activities in hyperlipidemia mice. FASEB J. 2024 Jan;38(1):e23399. doi: 10.1096/fj.202301564RR. PMID: 38174870. (IF:4.8).
(6) Xu M, Zhang P, Lv W, Chen Y, Chen M, Leng Y, Hu T, Wang K, Zhao Y, Shen J, You X, Gu D, Zhao W, Tan S*. A bifunctional anti-PCSK9 scFv/Exendin-4 fusion protein exhibits enhanced lipid-lowering effects via targeting multiple signaling pathways in HFD-fed mice. Int J Biol Macromol. 2023 Dec 31;253(Pt 4):127003. doi: 10.1016/j.ijbiomac.2023.127003. Epub 2023 Sep 20. PMID: 37739280. (IF:8.2)
(7) Xu M, Lei G, Chen M, Wang K, Lv W, Zhang P, Hu T, Gao J, Lu C, Mei Y, Xu Z, Bai Z, Hu H, Jiang Y, Tan S*. Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. EBioMedicine. 2021 Mar;65:103250. doi: 10.1016/j.ebiom.2021.103250. Epub 2021 Feb 26. PMID: 33647772; PMCID: PMC7921758. (IF:11.2)
(8) Bai Z, Xu M, Mei Y, Hu T, Zhang P, Chen M, Lv W, Lu C, Tan S*. Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia. Biomedicines. 2021 Nov 27;9(12):1783. doi: 10.3390/biomedicines9121783. PMID: 34944600; PMCID: PMC8698692. (IF:4.757)